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The development of many strategies for the prevention of
cardiovascular disease (CVD) presents an important policy
question for society: do the benefits of these programs and
interventions justify the investment in them? Preventive
strategies may provide attractive opportunities to avoid or
defer disease and disability, but they may have substantial
costs and must often be applied to many subjects in order to
reach the few in the group who will benefit the most.
Whether and how limited health care dollars should be
allocated to these activities is therefore an important area of
inquiry for health care policy makers and practitioners.
Economic considerations now dominate the health care
policy debate. Purchasers of health care have limited re-
sources and thus must determine the “value” of the services
of their spending decisions. The expanding array of CVD
preventive options, including novel markers of risk, new
imaging modalities, and innovative interventions, has drawn
particular attention as the pressure on health care budgets
increases. Currently, the U.S. uses almost 14% of its gross
domestic product (GDP) on health care reaching more than
$1.5 trillion per year (1). Health care inflation, initially
stabilizing in the mid-1990s, is again increasing at a more
rapid rate than the general consumer price index (2), leading
to marked increases in health insurance premiums (3). In
this economic environment, the failure of cardiologists to
take economic issues seriously may place their patients at a
distinct disadvantage in competing for scarce health care
resources with patients who have, or are at risk for, other
disease. Arguments in favor of the allocation of resources for
CVD prevention will increasingly need to be supported by
evidence of the value of the investment. Guideline commit-
tees need to consider the economic implications of their
recommendations and appeal not only to evidence of the
effectiveness of specific strategies but also to their value from
a societal perspective. Policy will not be based on this
information alone, but the information will be necessary to
persuade care purchasers of the worthiness of these activi-
ties.
In this discussion, what is currently known about the
value of selected preventive strategies for atherosclerotic
disease is reviewed, referring to the extra dollars spent on a
given program or intervention to produce extra health
benefits. In this context, what extra benefits these strategies
are producing, what they cost to produce these benefits, and
the ratio of the cost to the benefit are examined. Contro-
versies in this field that relate to valuing health care are also
considered. A proposal for an integrated policy designed to
determine the value of CVD prevention is presented in
conclusion.
COST-EFFECTIVENESS ANALYSIS OF
PREVENTIVE STRATEGIES: BRIEF OVERVIEW
A challenge for a society with finite resources is to deter-
mine which interventions and programs have the most
value. An approach to measuring value is to determine
which interventions yield the best extra or incremental
benefits (e.g., most quality-adjusted life-years [QALYs],
most years free from pain, and longest life in years) relative
to the extra resources (costs) required to produce those
benefits. Cost-effectiveness analysis is the most widely used
approach for the economic analysis of medical strategies and
interventions. It provides a way to compare incremental
costs and benefits, typically summarized as a cost-
effectiveness ratio (cost per unit of health outcomes
achieved).
Interventions that improve outcomes and decrease, or do
not change, costs are ideal yet all too rare. Strategies that
increase costs and worsen outcomes are easy to reject. The
challenge involves those strategies that improve outcomes
but require extra resources. Cost-effectiveness analysis pro-
vides an approach for the ranking of the relative value of
these options. When common definitions of health out-
comes are employed, it is possible to compare the opportu-
nity costs of various choices. “Opportunity costs” are the
value forgone by devoting resources to a given activity rather
than to their best alternative use.
For these ratios, no specific value ensures that a designa-
tion will be “cost-effective”—the distinction is relative and
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depends largely on the amount of money available to spend
on health care. For example, countries that spend a low
proportion of their GDP on health care (such as the United
Kingdom) would be expected to use a much lower threshold
to define what is economically attractive or “cost-effective”
than countries such as the U.S., that invest many more
dollars in health care. Regardless of the absolute bench-
marks used, the important concept is one of comparative
value. With a certain, fixed amount of money allocated to
health care, a policy maker is concerned with getting the
greatest health return on the investment. Therefore, spend-
ing on health interventions that produce many benefits for
a modest investment would always be preferred, in theory at
least, over expensive interventions that produce modest
benefits. Moreover, meaningful comparisons of value can-
not be made against an absolute benchmark; rather, they
must be measured in terms of alternative investment oppor-
tunities forgone. Thus, cost-effectiveness studies—when
conducted correctly—are incremental in that they compare
the added cost of achieving an additional unit of outcome by
switching between therapeutic options. A judgment about
what constitutes a reasonable return on investment depends
on the total budget available and a person’s role (e.g.,
purchaser, patient, caregiver, patient family member).
Many studies have pursued economic analyses of CVD-
preventive strategies. These studies have generally focused
on the incremental cost of an intervention per incremental
unit of health outcome and thus may be compared with
other common medical interventions (4). To provide a
survey of cost-effectiveness analyses performed for strategies
to prevent CVD, articles were identified describing cost-
effectiveness of lipid lowering, hypertension treatment,
smoking cessation, diabetes treatment, and exercise using
Medline covering the period from 1967 to 2001. The review
of the bibliographies of retrieved articles was used to identify
additional candidate articles. Studies of cost-effectiveness
were included if they calculated an incremental cost-
effectiveness ratio in terms of cost per year of life saved or
QALY gained. All costs were converted to 2001 U.S.
dollars using time-specific currency conversion rates and the
U.S. GDP deflator inflation index.
Lipid lowering. Several economic analyses of randomized
trial data have documented the economic attractiveness of
drug treatment compared with placebo (Tables 1 and 2).
The cost-effectiveness of the drug treatment is strongly
associated with the underlying risk for the patients, the
effectiveness of the drug and its cost. In general, pre-statin
drug therapy studies showed very modest lipid lowering and
equally modest reductions in major clinical events. In
contrast, 3-hydroxy-3-methylglutaryl–coenzyme A reduc-
tase inhibitors (“statins”) are much more effective in reduc-
ing low-density lipoprotein (LDL)-cholesterol, with aver-
age reductions in the range of 20% to 25%. Corresponding
relative reductions have been seen in clinical events. In
economics, however, absolute rather than relative differ-
ences determine the results of cost-effectiveness analysis.
Thus, a 20% reduction in mortality may save one life per
thousand treated in a very low-risk population and five lives
per hundred in a high-risk population. Granted that the cost
of a year of statin therapy will be about the same in these
two cases, it is clear that the 20% reduction in the high-risk
patients will be much more economically attractive. In
published studies, statins save lives at what is considered a
reasonable cost (less than $50,000 per year of life saved)
except for primary prevention in non-high-risk individuals.
The cost of the drug is the other important factor, and the
cost-effectiveness of this intervention will improve as less
expensive generic drugs become available.
Non-pharmacological therapy has also been shown to be
economically attractive. A low-cholesterol, low-fat diet has
been shown to be an efficient first step in treatment for
primary prevention for individuals with additional risk
factors (5). An analysis of numerous combinations of risk
factors by Prosser et al. (5) found that diet therapy was
highly cost-effective compared with no therapy for elderly
men age 75 to 84 with four risk factors (cost-effectiveness
ratio $2,000/QALY) and moderately cost-effective for
young women age 35 to 44 if they had three or more risk
factors (smoking, elevated blood pressure, elevated LDL,
low high-density lipoprotein [HDL]). However, the addi-
tion of a statin to a step 1 diet can be expensive. The
cost-effectiveness ratio was less than $50,000/QALY only in
patients with multiple risk factors, and in those without risk
factors it was greater than $140,000/QALY.
The cost of lipid lowering used in these analyses was
usually the wholesale price. However, the studies did not
routinely examine the impact of a statin cost when the
patent expires. A study using the Coronary Heart Disease
Policy Model estimated that a 50% decrease in drug cost
would reduce the cost-effectiveness ratio by 44% to 55% (5).
Thus, the cost-effectiveness of statin treatment will be more
favorable as generic drugs become available.
Smoking cessation. All published studies of smoking ces-
sation interventions indicate that the cost per year of life
saved is small compared with other accepted medical inter-
ventions (Table 3). Minimal physician counseling (4 min
initially, then 3 to 6 min during follow-up at $2.40 per min),
more intensive physician counseling (15 min), and nicotine
replacement therapy (patch or gum) have all been shown to
be relatively inexpensive per year of life saved. Lightwood
and Glantz (6) estimated that over 98,000 hospitalizations
(and over $3 billion of resource consumption) would be
prevented in the U.S. over seven years with a 1% reduction
in smoking. Krumholz et al. (7) found that the cost per year
of life saved with a nurse-based educational program was
less than $300.
Hypertension treatment. Numerous cost-effectiveness
studies of hypertensive treatment and screening have been
published (Table 4). However, different methodologies
preclude direct comparisons of their results. Many studies
were stated to be from a societal perspective, yet few studies
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Table 1. Lipid-Lowering: Primary Prevention Cost-Effectiveness Studies
Study, Year
Age Group
(Yrs) Gender
Cholesterol
(mg/dl)
Time
Horizon Treatment Comparator Cost-Effectiveness Comments
Weinstein and Stason, 1985 (38) 45–50 Male greater than 265 Unclear Cholestyramine No treatment $190,000/LY Based on Framingham risk data and
LRC-CPPT protocol.
Oster and Epstein, 1987 (39) 55–59 Male 290 Lifetime Cholestyramine No treatment $250,000/LY Based on Framingham risk data and
LRC-CPPT trial includes cost of
prolonged survival.
Kinosian and Eisenberg, 1988 (40) Adult Male greater than 265 7 years Diet (oat bran) No treatment $25,400/LY Based on Framingham risk data and
LRC-CPPT trial.
Martens et al., 1989 (41) Adult Male 310 Lifetime Simvastatin No treatment $36,000-83,000/LY Based on Framingham risk data and
LRC-CPPT trial and Dutch
data.
Goldman et al., 1991 (42) 55–64 Male greater than 300
mg/dl
Age 85 Lovastatin
20 mg/day
No treatment $75,000/LY Based on Coronary Heart Disease
Policy Model.
55–64 Female greater than 300 Age 85 Lovastatin
20 mg/day
$169,000/LY
55–64 Male 250–299 Age 85 Lovastatin
20 mg/day
$121,000/LY
Pharoah and Hollingworth, 1996
(43)
45–64 Male greater than 145 10 years Pravastatin No treatment $239,000/LY Assumptions from British Health
Care System. Used lipid lowering
but not economic data from
WOSCOPS.
Tosteson et al., 1997 (44) U.S. population Age 85 Education Usual care $3,700/LY $5.69 per person, 2% reduction in
cholesterol, uses Coronary Heart
Disease Policy Model.
WOSCOPS, 1997 (45) 45–64 Male LDL  155 Lifetime Pravastatin Placebo $34,000/LY Did not include extra costs due to
prolonged survival.
Pickin et al., 1999 (46) Adult Both 1.5% chance of
coronary events/
year
Lifetime Simvastatin No treatment $22,000/LY Effectiveness data based on
WOSCOPS.
Prosser et al., 2000 (5) 35–44* Male greater than 160 30 years Diet No treatment $87,000/QALY Based on Coronary Heart Disease
Policy Model, assumes 7.7%
decrease in LDL with diet. Data
provided for patients with no
other risk factors.
35–44* Female greater than 160 30 years Diet No treatment $251,000/QALY
65–74* Male greater than 160 30 years Diet No treatment $39,000/QALY
75–84* Female greater than 160 30 years Diet No treatment $40,000/QALY
35–44* Male greater than 160 30 years Pravastatin Diet $271,000/QALY
35–44* Female greater than 160 30 years Pravastatin Diet $775,000/QALY
65–74* Male greater than 160 30 years Pravastatin Diet $148,000/QALY
65–74* Female greater than 160 30 years Pravastatin Diet $159,000/QALY
Grover et al., 2000 (10) Non-diabetic adult Male LDL 135 HDL 39 Lifetime Pravastatin No treatment $26,000–43,000/LY Based on pravastatin effects on
Diabetic adult Male LDL 135 HDL 39 Pravastatin No treatment $8,000–16,000/LY lipids from the Cholesterol and
Recurrent Events (CARE) trial.
*Non-smoker, diastolic BP greater than 95 mm Hg.
CVA  cerebrovascular accident; HDL  high-density lipoprotein; LDL  low-density lipoprotein; LY  life years gained; LRC-CPPT  Lipid Research Clinics Coronary Primary Prevention Trial; QALY  quality adjusted
life years gained; WOSCOPS  West of Scotland Coronary Prevention Study.
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included indirect costs (decreased employment) or costs
arising from prolonged survival. Those that included indi-
rect costs found treatment to be more cost-effective than
studies including only direct medical costs. The assumed
treatment duration varied widely, and several studies did
not estimate costs and outcomes for the life of the
patient. The few consistent findings are that: 1) screening
for, and treatment of, mild or greater hypertension is
cost-effective when compared with other accepted health
care interventions ($10,000 to $40,000 per QALY
gained); 2) treatment is less cost-effective in young
women than in young men, and in the young than in the
elderly; and 3) treatment becomes more cost-effective as
pre-treatment blood pressure rises.
Diabetes treatment. The cost-effectiveness analyses of di-
abetes treatment indicate that intensive glucose control
improves outcome at a cost that is below other accepted
health care interventions (Table 5). Because diabetic pa-
tients are at a high risk for coronary artery disease, treatment
of hypertension and elevated lipids in these patients is
particularly economically attractive (8–11). The study,
based on the Diabetes Control and Complications Trial
Research Group (DCCT) Study, found that including the
extra cost of living longer with intensive therapy increased
the cost-effectiveness ratio from $32,000 to $34,000 per year
of life gained (12). If indirect costs are also accounted for,
the cost-effectiveness ratio drops (treatment becomes more
cost-effective) to $10,800 per year of life gained (13).
Although it is not directed at glucose metabolism, treatment
of middle-aged type II diabetics with angiotensin-
converting enzyme inhibitors was found to be economically
attractive (14).
Exercise programs. There is relatively little trial data on
the long-term effects of exercise, and consequently, few
studies have attempted to estimate the cost-effectiveness of
exercise programs. Assuming that sedentary behavior in-
creases the risk of heart disease by 1.9-fold, $6.4 billion
would be saved if the entire U.S. sedentary population began
a program of regular walking (15). Other studies estimate
that exercise programs cost money, particularly when time
lost to exercise is included, but that the benefits are large and
the cost per year of life gained remains well below $20,000
(Table 6).
Little is known about the cost-effectiveness of simulta-
neous risk-factor modification. However, several studies
have examined the cost-effectiveness of cardiac rehabilita-
tion after acute myocardial infarction. These programs use a
variety of interventions, including exercise, risk-factor man-
agement, and psychosocial counseling (16). A study from
Sweden found cardiac rehabilitation to be cost-saving when
indirect costs of work productivity were included (17).
Studies from the U.S. have estimated that cardiac rehabil-
itation increases direct costs by $5,500 to $11,100 per
life-year gained (18,19).Ta
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Table 3. Smoking Cessation Cost-Effectiveness Studies
Study, Year Population Treatment Comparator
Increased
Cessation
Rate Cost-Effectiveness Comments
Oster et al., 1986 (50) Males ages 35–69 Nicotine gum plus counseling Counseling 1.6% $6,000–9,500/LY
Females ages 35–69 Nicotine gum plus counseling Counseling 1.6% $10,000–13,900/LY
Cummings et al., 1989 (51) Males ages 35–69 Physician counseling Usual care 2.7% $1,000–1,400/LY Assumed 12 min of physician’s time.
Females ages 35–69 Physician counseling Usual care 2.7% $1,800–3,000/LY
Krumholz et al., 1993 (7) Post MI Nurse-mediated education leading
to 2.6% reduction in smoking
Usual care 26% $260/LY Cost-effectiveness less than $24,000/LY even
with program cost of $10,000 or success rate
of only 0.3%.
Fiscella and Franks, 1996 (52) Males ages 35–69 Nicotine patch plus counseling Counseling 6.4% $4,800–12,000/QALY
Females ages 35–69 Nicotine patch plus counseling Counseling 6.4% $5,800–7,700/QALY
Lightwood and Glantz, 1997 (6) U.S. smokers Hypothetical program with 1%
cessation rate
Usual care 1% Program dominates* 3.32 billion saved and 13,000 deaths prevented
over 7 years.
Cromwell et al., 1997 (53) U.S. smokers Minimal counseling Usual care 1.2% $4,400/QALY Cost per minute of physician’s time: $2.40.
U.S. smokers Full counseling Usual care 9.3% $1,700/QALY
U.S. smokers Transdermal nicotine and
minimal counseling
Usual care 21% $2,600/QALY
U.S. smokers Transdermal nicotine and full
counseling
Usual care 60% $1,500/QALY
U.S. smokers Nicotine gum and minimal
counseling
Usual care 2.3% $5,000/QALY
U.S. smokers Nicotine gum and intensive
counseling
Usual care 12% $2,300/QALY
Croghan et al., 1997 (54) Adults Program including nicotine
replacement
Usual care 22.2% $7,900/LY
Meenan et al., 1998 (55) Hospitalized patients In-hospital cessation and relapse
prevention
Usual care 8% $1,900/LY Intervention data from a Kaiser-based
randomized trial.
Stapleton et al., 1999 (56) Adults Nicotine patch plus counseling Counseling 5.1% $600–1,400/LY Based on United Kingdom costs.
*Less expensive and more effective.
LY  life years; MI  myocardial infarction; QALY  quality adjusted life years.
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Table 4. Hypertension Treatment and Screening: Cost-Effectiveness Studies
Study, Year Population
Time
Horizon
(yrs)
Treatment
Duration
(yrs)
Indirect
Costs
Treatment
(Comparator)* Cost-Effectiveness Comments
Stason and Weinstein, 1977 (57) 20-year-old male, diastolic BP 100 mm Hg Lifetime Lifetime No Drug treatment $71,300/QALY Assumed treatment of elderly is less beneficial
than treatment of young, estimates based
on Framingham Heart Study.
60-year-old female, diastolic BP
100 mm Hg
Lifetime Lifetime No Drug treatment $38,000/QALY
Stevens et al., 1984 (58) 35-year-old male Lifetime Lifetime No Screening and
treatment
$38,000/QALY Used Stason model with local costs and
effectiveness.
Nissinen et al., 1986 (59) Based on North Karelia Hypertension
program (Finland)
5 5 Yes Screening and
treatment
$8,500/QALY
Littenberg et al., 1990 (60) 40-year-old female Lifetime Lifetime No Screening and
treatment
$30,000/QALY Estimates based on trial data, results highly
sensitive to costs of anti-hypertensives.
60-year-old male Lifetime Lifetime No Screening and
treatment
$10,900/QALY
Edelson et al., 1990 (61) Patients 35–64 yrs with diastolic blood
pressure greater than or equal to
95 mm Hg
20 20 No Propranolol $13,600/QALY Based on the Coronary Heart Disease Policy
Model.
Patients 35–64 yrs with diastolic blood
pressure greater than or equal to
95 mm Hg
20 20 No HCTZ $20,500/QALY
Patients 35–64 yrs with diastolic blood
pressure greater than or equal to
95 mm Hg
20 20 No Nifedipine $39,500/QALY
Patients 35–64 yrs with diastolic blood
pressure greater than or equal to
95 mm Hg
20 20 No Captopril $90,200/QALY
Lasser and Wenzel, 1990 (62) German hypertensive men age 55–64 yrs Lifetime Lifetime No Drug treatment $39,200/LY Assumptions not clearly stated, no
discounting.
Kawachi and Malcolm, 1991 (63) 40-year-old men with diastolic blood
pressure 100 mm Hg
Age 64 Age 64 No Drug treatment $64,200/QALY Assumed no effect of treatment on coronary
heart disease.
Johannesson and Jonsson, 1991 (64) 35-year-old male Lifetime Lifetime Yes Drug treatment $23,000/LY Based on Framingham risk data and Swedish
cost data.
Johannesson et al., 1993 (65) Swedish Trial in Old Patients with
Hypertension (STOP)
Lifetime 2 Yes Diuretics,
Beta-blockers
$980/LY
Men aged 70–84 yrs
Swedish Trial in Old Patients with
Hypertension (STOP)
Lifetime 2 Yes Diuretics,
Beta-blockers
$3,100/LY
Women aged 70–84 yrs
Johannesson et al., 1993 (66) Metoprolol Atherosclerosis Prevention in
Hypertensives (MAPHY) study
Lifetime 5 Yes Metoprolol
(thiazides)
Metoprolol dominant
Johannesson, 1995 (67) Male 45–70 yrs diastolic BP 95–99 Lifetime 1 Yes Drug treatment $142/LY Meta-analysis of trial data used to determine
treatment benefit; Framingham data used
for risk of stroke and CHD.
Female 45–70 yrs diastolic BP 95–99 Lifetime 1 Yes Drug treatment $190/LY
*Comparator is no treatment unless otherwise indicated.
Costs adjusted to 2001 U.S. dollars using the GDP deflator.
BP  blood pressure; CHD  coronary heart disease; HCTZ  hydrochlorothiazide; LY  life years; QALY  quality adjusted life years.
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ISSUES IN COST-EFFECTIVENESS ANALYSES
Several methodological issues in cost-effectiveness analyses
are relevant to the assessment of preventive programs and
can affect how these programs are rated relative to alterna-
tive uses of funds. In this section, the issues of discounting,
the perspective of the analysis, the choice of effectiveness
measures, and the use of indirect costs are briefly reviewed.
The approach with regard to these issues may slant eco-
nomic analyses away from preventive interventions relative
to more acute care.
Discounting of future benefit. Discounting is employed
in economic analysis to take into account the time value of
costs and benefits. In general, people prefer to receive
desirable benefits as soon as possible and to delay costs
indefinitely. Discounting quantitatively incorporates these
preferences into economic analyses by weighing costs and
benefits less heavily the further into the future they occur.
Thus, a benefit in the future is not as attractive as an
immediate benefit, and a cost in the future does not weigh
as heavily as an immediate outlay.
To illustrate the crucial role of time preferences, consider
the case of two hypothetical means of achieving the same
health objective: Program A involves an immediate outlay of
$25,000, whereas alternative Program B requires no invest-
ment today but a $50,000 outlay 20 years from now (Table
7). Assuming that the two interventions are otherwise
identical, the decision as to which program is most attractive
depends solely upon the decision maker’s time preference. A
decision maker who is indifferent to the timing of events
would clearly prefer Program A, because $25,000 is less than
$50,000. To the contrary, a decision maker who discounts
future income streams at a 5% annual rate would find
Program B more attractive. To see why this is so, consider
an investor who can earn a 5% annual return on savings.
Table 5. Diabetes Treatment and Screening: Cost-Effectiveness Studies
Study, Year Population
Time
Horizon
(yrs) Treatment Comparator Cost-Effectiveness Comments
DCCT, 1996
(12)
Candidates for the
DCCT trial
17% of diabetics
on insulin
Lifetime Intensive therapy Conventional
therapy
$31,600/LY
Golan et al.,
1999 (14)
50-year-old
patients with
new type II
diabetes
Lifetime ACE inhibitors
for all
Screening for
microalbuminuria
$7,700/QALY
Gray et al.,
2000 (68)
Type II diabetics 10 Intensive therapy Conventional
therapy
$2,000/event-free
LY
Cost estimates from United
Kingdom.
Almbrand et al.,
2000 (69)
Diabetics with
acute MI
Lifetime Glucose-insulin
infusion
followed by
SQ insulin
Conventional
therapy
$18,300/QALY Based on DIGAMI trial. Included
indirect and future costs.
Clarke et al.,
2001 (11)
Type II diabetics
greater than
120% of ideal
body weight
Lifetime Metformin Conventional
therapy
Metformin
dominates*
Cost estimates from United
Kingdom. Effectiveness from
randomized trial data.
Metformin saved 258 pounds
(1997) over 10.8 years.
*Less expensive and more effective.
ACE  angiotensin converting enzyme; DCCT  Diabetes Control and Complications Trial Research Group; DIGAMI  Diabetes Mellitus Insulin Glucose Infusion in
Acute Myocardial Infarction; LY  life years; MI  myocardial infarction; QALY  quality adjusted life years; SQ  subcutaneous.
Table 6. Exercise Programs: Cost-Effectiveness Studies
Study, Year Population
Time
Horizon
(yrs) Treatment Comparator Cost-Effectiveness Comments
Hatziandreu et al.,
1988 (70)
Men age 35 30 Jogging No exercise $15,400/QALY Includes indirect costs from time
lost due to exercising.
Munro et al.,
1997 (71)
Men and women
over age 65
Lifetime Supervised exercise
twice weekly
No exercise $533/LY
Lowensteyn et al.,
2000 (72)
U.S. population Lifetime Unsupervised
exercise
No exercise less than $13,000/LY Based on the Cardiovascular
Disease Life Expectancy
Model.
Men with
cardiovascular
disease
Lifetime Supervised exercise No exercise less than $16,000/LY
LY  life years; QALY  Quality adjusted life years.
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This investor could take the $25,000 that he might other-
wise invest in Program A and place it in an interest-bearing
bank account. In 20 years, the original $25,000 would have
grown to $66,332 ($66,332 equals the sum of $25,000 times
1.0520), thus permitting the investor to invest in Program B
while pocketing the remaining $16,332. Indeed, Program B
is preferred to Program A by any decision maker whose
discount rate is in excess of roughly 3.5%, because at any
discount rate above 3.5%, the discounted value of $50,000 in
20 years is less than $25,000.
The fact that individuals and society value the present
more highly than the future significantly affects decisions
regarding preventive interventions. If a program incurs costs
immediately but its health effects accrue in the future, the
positive effects of the program are significantly smaller when
discounting is taken into account, whereas the full effect of
the current costs is felt. Thus, many programs that incur
substantial benefits may not be cost-effective, because those
benefits may arise too far into the future.
Some experts advocate discounting costs but not benefits
(20,21). However, a practical problem emerges in this
situation. Discounting costs but not benefits can lead to the
peculiar result of improving the cost-effectiveness of many
programs by the indefinite delay of their implementation.
That is, discounting costs but not benefits suggests that any
program would be better implemented “next year.” This
phenomenon of “policy paralysis” or the “infinitely delayed
splurge” also emerges when any discount rate lower than
that applied to resource costs is applied to the health
benefits (22).
Using the approach of discounting future costs and
benefits, can it ever be more efficient to invest today’s dollars
in the uncertain hope of a benefit some time in the future?
The answer is mixed. Some preventive interventions are
highly cost-effective; others are less so. Some immediate
treatment interventions compare favorably with prevention;
others do not. A 1995 analysis of 500 different life-saving
interventions found that neither form of health investment
dominates the other (4). Nevertheless, the issue of whether
to value future benefits less than current benefits, which may
place preventive programs at a relative disadvantage com-
pared with acute interventions, results in some serious
tension in the economic analysis of preventive interventions.
Perspective of the analysis. Preventive interventions affect
patients, families, providers, developers of new drugs and
other medical technologies, insurers, managed care organi-
zations, governments, taxpayers, and society. More often
than not, the implementation of a new medical technology
or intervention—or its inclusion in a health maintenance
organization formulary—serves to redistribute costs and
benefits among these groups. Assessments of any interven-
tion’s appropriateness and cost-effectiveness may differ dra-
matically depending on a group’s perspective. For example,
an intervention designed to reduce hospital lengths of stay
may benefit health care institutions and payers by lowering
inpatient hospital costs, while simultaneously imposing
additional time and productivity burdens on patients and
their families. Depending on the perspective of the analysis,
assessments of the program’s attractiveness may differ not
only in magnitude but even in direction.
Published academic evaluations typically focus on public
health and global resource allocation decisions. For this
reason, the U.S. Panel on Cost-effectiveness Analysis in
Health and Medicine recommends that analysts adopt a
societal perspective in which all costs and benefits are taken
into account, regardless of whom they affect (23). The
societal perspective is the only one that does not require
some party in the treatment decision to lose in order that
someone else might gain. The hospital perspective, for
example, focuses on short-term cost and benefits. What
happens to patients after being discharged is irrelevant to
this perspective. The managed care company’s perspective
takes into account the fact that an individual patient is likely
to keep health insurance with that company for only two to
three years on average. Paying for interventions that might
yield benefits a decade or more in the future is of no value
from this perspective. Thus, while individuals in health care
rarely look at the societal perspective, it is in the public
interest to keep this perspective in the forefront of the
discussion while other perspectives are considered. One
issue that often evolves in this context is that the societal
perspective ignores important transfer payments (such as the
cost shift from health care purchasers to patients in the
length-of-stay example) from one member of society to
another: although such redistributions are irrelevant from a
societal viewpoint, they may be of paramount importance to
the parties affected. Given the fragmented nature of the
U.S. health care system and the painful transfers that must
inevitably result from any re-allocation of scarce resources, it
is unlikely that cost-effectiveness criteria, administered from
the societal perspective, will emerge any time soon as
blueprints for public decision making. Nevertheless, an
efficiency-based analysis can help to illuminate the clinical
and economic costs that society incurs by failing to appor-
tion its health care resources where they will do the greatest
good. Such an approach can add support to the develop-
ment of more ethically defensible prevention policies.
Deciding on the effectiveness measure. An advantage of
economic analysis is that expectations about the effective-
ness of a given strategy must be explicitly stated. If evidence
about the effectiveness of a given intervention is weak (or
non-existent), then it will be revealed in the methods and
exposed for the knowledgeable reader.
Table 7. Impact of Time Value on Preferences
Year Program A Program B
0 $25,000 $0
20 $0 $50,000
Total outlay $25,000 $50,000
NPV at 3% $25,000 $27,684
NPV at 5% $25,000 $18,844
NPV  net present value.
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The choice of measure of benefit on an intervention may
determine its implementation. The prevention of death due
to one disease may not be a valuable outcome if overall life
expectancy is unchanged because of competing risks due to
other illnesses. Preventing sudden death so that people
instead die of cancer, without a significant net gain in
quantity or quality of life, is not an economically attractive
investment, even if the intervention is efficient in reducing
sudden death. As a result, many analyses favor more global
estimates of benefit that go beyond disease-specific metrics.
In addition, patients may value quality of life more than
survival. Economic analyses have attempted to incorporate
patient preferences (also called utilities)—or how patients
value different states of disease and disability—in their
evaluations of preventive or other interventions. These
preferences allow the calculation of QALYs and arithmet-
ically incorporate both quality and quantity of life. Unfor-
tunately, the methods available to assess patient preferences
are still rudimentary. In the evaluation of preventive ser-
vices, it is particularly important to value appropriately the
transition from being well to being ill. Much of the value of
preventive programs consists in preventing this transition
and in allowing individuals to avoid disability. Underesti-
mating the preference for wellness is another challenge to
the proper evaluation of preventive services.
Measuring indirect costs. Another challenge in perform-
ing these economic analyses is fully accounting for indirect
costs, those resources expended that are not directly related
to medical care. These costs include days lost from work,
time diverted from other (non-work) productive activity,
dollars devoted to caregiving activities, the value of caregiver
time when provided outside the labor force (e.g., by family
caregivers), or lost enjoyment associated with the interven-
tion (e.g., losing the pleasure associated with smoking as a
result of adherence to a smoking cessation regime). These
costs can be considerable and may offset much of the
investment in the preventive intervention. Despite the
importance of these costs, they are often not included in
cost-effectiveness analyses and are mostly invisible to those
who purchase care. However, there are economic analyses
that have measured many of these, and there are economic
methodologies to measure all of them. From a societal
perspective, they may account for the greatest recovery of
costs from investments in prevention.
COST EFFECTIVENESS VERSUS PUBLIC POLICY
Health policy decisions often appear inconsistent with
economic analyses for at least three reasons. First, the
assumptions underlying economic analysis are that decision
makers will behave in a rational fashion. Specifically, they
will always choose to do the most efficient thing regardless
of who gains and who loses. This is clearly not the case.
Americans frequently support expensive programs that
promise little health benefit while, at the same time,
forgoing opportunities to invest in much more cost-effective
strategies for health improvement (24). To cite just a few
examples, the U.S. spends approximately $115 million per
year on benzene emission control to save an estimated five
years of life (25). If this same amount were instead spent on
collapsible automobile steering columns, the nation could
save an additional 1,684 years of life (26). Similarly, adher-
ing to the 1990 amendments to the Clean Air Act will cost
more than $5 million for each year of life that is saved as a
result of reduced emission of toxic pollutants.
These inconsistencies can have important consequences
both for the public health and for the public purse. Tengs
and Graham (27) performed an analysis of 287 lifesaving
interventions for which information on both cost-
effectiveness and current levels of implementation was
available. They determined that a simple redistribution of
resources among those programs could prevent 60,000
premature deaths (resulting in a long-run gain of over
600,000 life-years) each year in the U.S., with no net
increase in resource consumption. Viewed another way,
these findings suggest that a re-allocation of lifesaving
resources to the most cost-effective activities would free up
$31 billion per year in the U.S., with no net loss of life.
What explains this inefficiency in the public prioritization
of health risks? Part of the answer lies in the diffusion of
authority. Lifesaving resources are not easily transferred
from one domain of intervention (such as occupational
safety, environmental health, or infectious disease control)
to another. A single policy maker rarely has the authority to
shift funds from pollution abatement to childhood immu-
nization or from mammography for pre-menopausal women
to automobile airbag installation. Indeed, entirely different
funding mechanisms operate from one domain to the next;
the compliance costs of many environmental interventions,
for example, are borne by private businesses and their
customers, whereas other health programs (such as epide-
miological outbreak investigations) are funded directly with
tax dollars. In addition, while some public health measures
can be implemented at the behest of individual decision
makers, many others (such as treatment of hyperlipidemia)
rely on the participation of millions of independent decision
makers with widely varying priorities, information, and
resources.
A second reason why results of economic analysis often
do not drive public policy is the lack of adequate data to
perform credible economic analyses. In the state of Oregon,
for example, policy makers undertook—and then more or
less ignored—an ambitious, formal evaluation in 1989 to
guide them in rationing the state’s Medicaid services. A
draft priority list, derived on the basis of the cost-
effectiveness criterion, was revealed in May 1990. In the
presence of overwhelming criticism and ridicule, it was
almost immediately withdrawn. Commissioners went back
to the drawing board and began work on a revised ranking
scheme. By March 1993, the commission members had
virtually abandoned the priorities suggested by the formal
analysis in favor of a softer, intuitive apportionment process
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(28–31). The effort in this case was well intentioned, but
the available data were simply not adequate to support a
global ranking of medical interventions.
The third reason why economic analysis does not deter-
mine public policy has been called “the rule of rescue” (29).
Simply put, medical professionals are unable to stand by
while an identifiable person’s life is threatened if some
possibly effective therapy is available to treat that person.
The concept that “we did everything we could” is not
rational from a decision-making point of view, but it is very
human. Policy makers are not immune to this effect.
Political lobbies and special interests can greatly influence
resource allocation decisions. Good cases in point include the
creation of the federally funded Acquired Immune Deficiency
Syndrome Drug Assistance Programs, the federal govern-
ment’s decision to finance dialysis therapy for all U.S. end-
stage renal failure patients, and the broad political support of
mammograms for women between the ages of 40 and 49 years.
Clearly, the principles of cost-effective resource allocation
do not capture all the essential elements that influence
policy decisions. The recognition of the various issues that
are important in influencing perceptions of the value of
preventive programs is essential in understanding the bar-
riers to making decisions about programs solely by using
cost-effectiveness ratios. It is these issues that make it
difficult to answer directly whether we can afford prevention
programs and what role they should play in our portfolio of
health care expenditures. In the following section, selected
issues that influence the debate and perceptions about the
value of these interventions are reviewed.
COST EFFECTIVENESS
VERSUS TOTAL SYSTEM COSTS
Despite the opportunity to make an economically attractive
investment, society may resist devoting a large, dispropor-
tionate pool of resources to one condition or group of
individuals. For example, the use of statins is an economi-
cally attractive intervention for many people with, or at risk
for, CVD. In May 2001, the National Cholesterol Educa-
tion Program published a report outlining revised guidelines
for cholesterol control. In addition to many dietary and
behavioral changes, the panel recommended a significant
increase in the number of people who take lipid-lowering
drugs (32). Applying the panel’s recommendations to the
population of the U.S., it is estimated that 36 million
Americans should be taking a lipid-lowering agent. The
report, however, did not consider the system cost of imple-
menting the recommendation. Taking the monthly retail
price of an inexpensive statin as an example, and assuming
a 5% rate of discounting costs in future years, this recom-
mendation would cost society more than $500 billion in
direct drug costs over the next 20 years. This allocation of
resources would cost nearly $1,200 per person per year; that
is, 29% of the current annual per capita (average) spending
on health care in total (33). The allocation of these resources
is expected to result in a lower rate of vascular disease and
possibly other disease conditions, but it will almost certainly
be at the expense of other potential medical investments.
Finding that a therapy is economically attractive is not
enough to ensure that it will be widely adopted. There must
also be enough money in the budget to pay for it.
The American Heart Association (AHA), in concert with
the Centers for Disease Control, has committed itself to
achieve a 25% reduction in CVD by 2010. The AHA has
not explicitly considered what the country should be willing
to spend to achieve this goal, what it will cost to reach this
target, or what other investments would be passed over as a
result. Is it presumed that the country should meet this goal
at any cost? If the most efficient use of prevention dollars
(assuming that a finite amount is available) is to devote them
to the prevention of CVD, should it be done at the expense
of efforts to prevent other conditions? Pure economic
analysis would favor the efficiency of that approach; how-
ever, politics and human nature would not.
Issues of blame and controllability. The attribution of
death to a voluntary, controllable cause or behavior (like
smoking) appears to play an important role in determining
the degree of social sympathy that is likely to be provoked
and, correspondingly, the level of difficulty experienced in
securing financial support for prevention and treatment
programs (34). Public funding for programs to prevent the
spread of human immunodeficiency virus (widely perceived
to be a voluntary, controllable risk) generally meets a great
deal of opposition despite overwhelming evidence that
many such programs actually save society money as well as
lives. By contrast, even the specter of cancers from invol-
untary, uncontrollable sources (such as air pollution,
second-hand tobacco smoke, and electromagnetic fields)
provokes widespread calls for greater research and funding.
The human propensity to feel less charitable toward those
perceived to be taking on voluntary or controllable risks is
particularly pertinent in view of findings by psychological
researchers that people almost universally underestimate the
importance of situational (or environmental) factors, as
opposed to personal qualities, in determining the behavior
of individuals. Indeed, this tendency appears to be so
deep-rooted and so widespread that psychologists have
termed it the fundamental attribution error (35). Studies also
show that the proclivity to over-assign blame to the indi-
vidual when considering other peoples’ behavior does not
extend to the evaluation of one’s own behavior; one usually
takes credit for successes while blaming failures on the
surrounding environment. With these findings in mind, it is
perhaps not surprising that people feel less sympathy for
cigarette smokers (a distinct minority of the population)
who contract lung cancer than for inactive people with poor
dietary habits who fall victim to coronary heart disease.
A perverse sense of fairness seems to exist. There is less
sympathy for lives in peril when the individuals at risk are
judged to have “brought it on themselves.” The problem,
once again, is that what is perceived as fair from the point of
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view of causation need not be fair—or efficient—with
regard to final outcomes and the efficient allocation of scarce
societal resources.
Expectations of budget neutrality. Another obstacle con-
spiring against increased investment in prevention programs
is the public expectation that such interventions should pay
for themselves. This is a view that is expressed with growing
frequency in public discussions on health, social programs,
and the environment. Well-intentioned prevention advo-
cates are fond of arguing that a dollar invested today in a
particular program produces more than a dollar’s worth of
savings later. Recently, public figures have taken up the call,
insisting that health, social, and environmental programs
should “pay for themselves.” Terms such as “budget-
neutrality” and “pay as you go” appear frequently in law-
makers’ discussions of Medicare and Medicaid financing.
Indeed, the idea that new health initiatives should pay for
themselves has the force of law. According to the Balanced
Budget Act of 1997, no Medicaid waivers under Section
1115 of the Social Security Act may be granted unless states
can demonstrate the “budget neutrality” of their proposed
initiatives. This same law requires that all base-year Pro-
spective Payment Service Medicare outlays be “budget-
neutral” in their impact. The phrase “budget-neutral” ap-
pears 18 times in the text of the recently enacted
congressional budget appropriations law concerning Medi-
care, Medicaid, and the Children’s Health Insurance Pro-
gram.
The idea that “an ounce of prevention is worth a pound
of cure” is well entrenched in the human psyche, makes an
excellent media sound bite, yet is rarely true. A recent
compilation of 500 economic evaluations of lifesaving in-
terventions found only a small fraction of instances in which
a medical prevention program paid for itself (4). In the large
majority of situations, increased survival carried with it new
long-term competing risks and additional resource costs
that wiped out any short-term savings attributable to the
prevention program.
To a cost-effectiveness analyst, budget neutrality is not a
reasonable expectation nor is it good policy. When it comes
to most public—and virtually all private—expenditures,
people recognize that they must sometimes draw down their
wealth to pay for the things they most desire. Nobody
objects to spending good money when the benefits are
believed to exceed the costs. People understand the idea of
return on investment. Budget neutrality, however, demands
return without investment (i.e., a free lunch). It is the search
for a money-making program disguised as a health inter-
vention, which if used as a public-policy hurdle, will force
individuals to cast aside many sound investments in health
promotion and disease prevention (36,37). For instance,
suppose that a new therapy is shown to safely and reliably
decrease cigarette smoking at a cost of $10,000 per QALY
gained. With budget neutrality, either the therapy could not
be adopted or some other health care service would have to
be cut back or eliminated.
CONCLUSIONS
In summary, this task force has reviewed the major evidence
on the value of preventive therapies. As in other areas of
medicine, prevention is a complex mix of different strategies
and technologies with widely varying economic attractive-
ness. Although primary prevention is more attractive on an
emotional level, economic analysis usually finds secondary
prevention to be more efficient. This is due to the rather
simple fact that patients who have clinical disease are at
higher risk, and therefore more likely to benefit, than a
group of lower-risk subjects, only a few of whom will ever
develop disease. The number needed to treat to save a life is
much smaller in secondary prevention, and hence the cost to
save a life is also smaller (more favorable). The decision to
implement a preventive strategy on a widespread scale
depends not only on the economic attractiveness but also on
the cost of the whole program to the health system. The
purchasers’ perspective may also “tilt” a decision because
benefits of a long-term prevention strategy may not accrue
to the organization required to make the initial investment.
Also, an economically attractive intervention is no bargain if
there is no money in the budget to pay for it or if it diverts
money away from other important social priorities such as
housing and education. Finally, economic analysis is just
one part of the complex equation of clinical and policy
decision making and often is trumped by other consider-
ations. Policy makers do not display the “steely” rationality
implicit in economic theory, and physicians cannot sit by
and do nothing if a patient’s life is threatened, even if all
they can do is very expensive and may have only potential for
benefit.
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Task Force #3—Getting
Results: Who, Where, and How?
Philip A. Ades, MD, FACC, Co-Chair, Thomas E. Kottke, MD, FACC, Co-Chair,
Nancy Houston Miller, RN, BSN, John C. McGrath, PHD, N. Burgess Record, MD, FACP,
Sandra S. Record, RN
The provision of preventive cardiology services in the U.S.
will require a combination of the medical model of care and
of community preventive health programs. These ap-
proaches are complementary, synergistic, and each essential,
with a goal of “getting results” in the broadest possible
population. Organizations such as the American Heart
Association (AHA) and the National Heart, Lung, and
Blood Institute (NHLBI) have outlined algorithms for the
primary and secondary prevention of coronary heart disease
(CHD) (1–3), but it is a combination of medical-model and
community program approaches that will deliver preventive
care. In that the mortality from heart disease has dropped by
40% since 1970, the present approach is not without
positive results (4). The goal of this discussion is to describe
the types of clinical, community, and media programs that
have been effective in decreasing coronary risk in the general
public. Because an understanding of the principles of media
and communication are crucial to the success of any health
promotion program, the principles of effective media and
communication are briefly reviewed.
Physicians are generally well trained in defining the
presence of coronary risk factors and in the medical man-
agement of hyperlipidemia, hypertension, and diabetes.
Further training of cardiovascular (CV) specialists as leaders
in prevention (see Task Force Report #5) will assist in this
effort. Physicians are, however, far less capable of managing
and influencing lifestyle-related risk factors such as tobacco
use, diet, physical inactivity, and the consequences of
obesity. In addition, a brief office encounter does not lend
itself to the counseling and follow-up necessary to initiate a
change in unhealthy lifestyles. Broadening the physician
encounter to include non-physician personnel and commu-
nity resources will yield a greater impact in reducing
coronary risk. Furthermore, a high percentage of young
adults do not regularly visit physicians until the presence of
lifestyle-related conditions such as CHD or type II diabetes
are detected; thus, the role of public policy, school and
worksite programs, and mass-media should be emphasized.
Physicians, as role models and opinion setters, play a crucial
role in supporting the design and development of commu-
nity programs.
Numerous documents and position statements define
treatment goals for the prevention of CHD (2,5). Less clear
are the processes by which Americans might reach these
goals. It is only through a combination of community
programs, medical referral and treatment, and mass media
approaches to screening and therapy that the majority of
Americans will attain appropriate risk factor levels to sig-
nificantly reduce the incidence of CHD.
PROGRAMS OF GOVERNMENTAL AND
NON-GOVERNMENTAL ORGANIZATIONS
National Cholesterol Education Program. The National
Heart, Lung, and Blood Institute (NHLBI) of the National
Institutes of Health (NIH) launched the National Choles-
terol Education Program (NCEP) in November 1985 (5).
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